A top German health authority, the Joint Federal Committee of doctors, health insurers and hospitals, has found no added benefit for the Alzheimer's drug donanemab compared to older treatment methods. The decision was made in the same way as it previously did for lecanemab, which was the first drug approved in Germany that directly targets protein deposits in the brain. No benefit was demonstrated for patients with mild dementia, and there was no data substantiating any benefits for those with mild cognitive impairment. The assessment will impact negotiations regarding the price of the drug and the potential withdrawal of both drugs.